Research programme: synthetic macrocycles - Ensemble Therapeutics

Drug Profile

Research programme: synthetic macrocycles - Ensemble Therapeutics

Alternative Names: E-36041; IDO checkpoint inhibitors; ubiquitin proteasome inhibitors

Latest Information Update: 19 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ensemble Discovery
  • Developer Ensemble Therapeutics; Novartis
  • Class Antineoplastics; Macrocyclic compounds; Small molecules
  • Mechanism of Action Checkpoint kinase inhibitors; Cyclophilin D inhibitors; Cyclophilin inhibitors; Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Inhibitor of apoptosis protein inhibitors; Interleukin 17 receptor antagonists; PCSK9 protein inhibitors; Tryptophan oxygenase inhibitors; Ubiquitin thiolesterase modulators; USP28 protein inhibitors; Usp30 protein inhibitors; USP9X protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Inflammation; Rheumatoid arthritis
  • Research Amyotrophic lateral sclerosis; Cardiovascular disorders; Hepatitis B; Parkinson's disease; Reperfusion injury
  • Discontinued Diabetes mellitus; Pain

Most Recent Events

  • 19 Jan 2017 Discontinued for Diabetes mellitus in USA (PO)
  • 19 Jan 2017 Discontinued for Pain in USA (PO)
  • 19 Jan 2017 Early research in Amyotrophic lateral sclerosis in USA (PO) before January 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top